<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30852">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705066</url>
  </required_header>
  <id_info>
    <org_study_id>2015-8400</org_study_id>
    <nct_id>NCT02705066</nct_id>
  </id_info>
  <brief_title>Citicoline Effects on Cortical Membrane Structure and Function</brief_title>
  <official_title>Citicoline Effects on Cortical Membrane Structure and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Bio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Hakko Bio Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The goal of this project is to determine the effects of 6-week dietary supplementation with
      one of two doses of citicoline (250 mg/d, 500 mg/d) or placebo on prefrontal cortical
      membrane dynamics (31P-MRS) and event-related functional activation (fMRI) in healthy
      middle-aged adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the effect of citicoline supplementation on cortical structure and function in
      healthy middle-aged adults. Test 1: The effect of citicoline (500 mg/d) compared with
      placebo on event-related anterior cingulate cortex (ACC) activation during sustained
      attention by fMRI. Test 2: The effect of citicoline (500 mg/d) compared with placebo on
      reaction time and increasing accuracy on the sustained attention task (CPT-IP). Test 3: The
      effect of citicoline compared with placebo on phosphodiester (PDE) and b-NTP levels in the
      ACC by 31P-MRS. Test 4: ACC activation and CPT-IP performance (fMRI) and ACC PDE levels
      (31P-MRS) following high-dose citicoline (500 mg/d) compared with placebo at Week 3. Test 5:
      The effect of low-dose citicoline (250 mg/d) compared with placebo on an ACC activation and
      CPT-IP performance (fMRI) and ACC PDE levels (31P-MRS). Test 6: Among all subjects (n=60),
      the relationship between baseline red blood cell (RBC) omega-3 fatty acid (EPA+DHA) levels
      and ACC activation, ACC PDE levels, or the effects of citicoline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phosphodiester (PDE) concentrations in the ACC by 31P-MRS</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>b-NTP concentrations in the ACC by 31P-MRS</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood oxygenation level-dependent signal in the ACC during sustained attention by fMRI</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction time (ms) on an attention task (CPT-IP)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy (percent correct) on an attention task (CPT-IP)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline red blood cell (RBC) omega-3 fatty acid (EPA+DHA) levels</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo (Cellulose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognizin 250 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognizin 500 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citicoline supplement</intervention_name>
    <arm_group_label>Cognizin 250 mg/day</arm_group_label>
    <arm_group_label>Cognizin 500 mg/day</arm_group_label>
    <other_name>Cognizin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplement</intervention_name>
    <description>Cellulose</description>
    <arm_group_label>Placebo (Cellulose)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent;

          -  Ages 40-60 years old;

          -  Right handed.

          -  If female, not pregnant (as determined by a positive pregnancy test); and agrees to
             use one of the following methods of birth control: abstinence from sexual
             intercourse, barrier (diaphragm or condom), or oral/injectable contraceptive;

        Exclusion Criteria:

          -  Contraindication to an MRI scan (i.e., braces, claustrophobia, pacemaker etc);

          -  A history of a major medical (e.g., diabetes) or neurological illness (e.g.,
             epilepsy);

          -  Body mass index (BMI) â‰¥ 30;

          -  An IQ &lt;75 and &gt;130;

          -  A positive urine drug test (nicotine dependence is permitted);

          -  Personal history of a DSM-5 Axis I psychiatric disorder;

          -  Requiring treatment with a drug which might obscure the action of the study
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert McNamara, PhD</last_name>
      <phone>513-558-5601</phone>
      <email>robert.mcnamara@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert McNamara, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>February 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
